McMaster University

McMaster University

Andrew Arnold

[BACK]
Photo Biography, contacts and additional information
Andrew Arnold

MD (London). ECFMG, MRCP, FRCPC

Professor Emeritus, McMaster University
Department of Oncology, Division of Medical Oncology

Contacts



Email: arnolda@hhsc.ca

 

 

Enter email below for mentorship availability checker, or leave empty to disable:

 

Academic Interests

Dr. Arnold has a long standing interest in lung and breast cancer clinical trials. More recent interests include drug safety in clinical trials and, more specifically, determining causality of adverse events.

Selected Publications

  1. Laurie SA, Gauthier I, Arnold A, Shepherd FA, Ellis PM, Chen E, Goss G, Powers J, Walsh W, Tu D, Robertson J, Puchalski TA, Seymour L. Phase I and pharmacokinetic study of daily oral AZD2171, an inhibitor of vascular endothelial growth factor tyrosine kinases, in combination with carboplatin and paclitaxel in patients with advanced non-small-cell lung cancer: the National Cancer Institute of Canada clinical trials group. J Clin Oncol. 2008 Apr 10;26(11):1871-8.
  2. Arnold AM, Seymour L, Smylie M, Ding K, Ung Y, Findlay B, Lee CW, Djurfeldt M, Whitehead M, Ellis P, Goss G, Chan A, Meharchand J, Alam Y, Gregg R, Butts C, Langmuir P, Shepherd F; National Cancer Institute of Canada Clinical Trials Group Study BR.20. Phase II study of vandetanib or placebo in small-cell lung cancer patients after complete or partial response to induction chemotherapy with or without radiation therapy: National Cancer Institute of Canada Clinical Trials Group Study BR.20. J Clin Oncol. 2007 Sep 20;25(27):4278-84.
  3. Arnold A, Ayoub J, Douglas L, Hoogendoorn P, Skingley L, Gelmon K, Hirsh V, Eisenhauer E. Phase II trial of 13-cis-retinoic acid plus interferon alpha in non-small-cell lung cancer. The National Cancer Institute of Canada Clinical Trials Group. J Natl Cancer Inst. 1994 Feb 16;86(4):306-9. No abstract available.
Search for publications for Dr. Arnold on PubMed
Valid XHTML 1.0 Transitional Level Double-A conformance, W3C WAI Web Content Accessibility Guidelines 2.0